


## REMARKS

Applicants are filing this Amendment concurrently with a Response to the November 15, 2005 Restriction Requirement in which Applicants have elected the invention of Group I (claims 1-3, 5, 17, 18 and 25-33, drawn to an isolated polynucleotide of SEQ ID NO:1 and cells comprising this polynucleotide). Claims 2 and 17-29 have been cancelled without prejudice or disclaimer. Claims 1, 3-5 and 30-33 have been amended. The amendments presented herein are fully supported by the specification and claims as originally filed. Accordingly, no new matter has been added by the present amendment.

## CONCLUSION

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

  
Ingrid A. Beattie, Reg. No. 42,306  
Attorney for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623